Systemic and local estrogen metabolism in healthy women compared to endometrial cancer patients|
|- candidate number||24127|
|- NTR Number||NTR5780|
|- ISRCTN||ISRCTN no longer applicable|
|- Date ISRCTN created|
|- date ISRCTN requested|
|- Date Registered NTR||20-mrt-2016|
|- Secondary IDs||NL55799.015.15 |
|- Public Title||Systemic and local estrogen metabolism in healthy women compared to endometrial cancer patients|
|- Scientific Title||Systemic and local estrogen metabolism in healthy women compared to endometrial cancer patients|
|- ACRONYM||TEC study|
|- hypothesis||This study is a pilot study to obtain an idea of the complete estrogen metabolism in pre- and post menopausal healthy women, compared to endometrial cancer patients. The complete estrogen metabolism is defined as the serum steroid levels and the local estrogen metabolism in endometrial (cancer) tissue. This will result in an overview of patients’ specific estrogen metabolism; furthermore, the level of each individual serum steroid and endometrial tissue enzyme levels per group will be compared to indicate if there are any differences|
|- Healt Condition(s) or Problem(s) studied||Endometrial carcinoma, Estrogens|
|- Inclusion criteria||Patients with;|
- Hysterectomy needs to be preformed because of endometrial cancer or benign indication (like prolapse, menorrhagia, uterus myomatosis)
- Menopausal status is known
- Blood collection need to be allowed
- Informed consent is given
- No history of malignancies in the previous 5 years
- Minimum age: 18 years
|- Exclusion criteria||Patients with;|
- Neoadjuvant treatment defined as chemotherapy and/or radiotherapy
- Aged under 18 years
|- mec approval received||yes|
|- multicenter trial||no|
|- Type||2 or more arms, non-randomized|
|- planned startdate ||1-mei-2016|
|- planned closingdate||1-nov-2017|
|- Target number of participants||90|
|- Interventions||Endometrial tissue analysis|
mRNA analyses will be preformed using real-time PCR.
RNA will be isolated with Trizol reagent and assesses spectrophotmetrically for quantity and purity and c DNA will be synthesized. Primers for PCR amplification for HSD17B1, HSD17B2, STS, SULTE1 and Aromatase are commercially available and will be used.
Enzyme activity levels will be measured using our recently developed method by Liquid chromatography–mass spectrometry (LCMS).
Method; frozen samples will be homogenized with a blender in a radioimmunoprecipitation assay buffer, debris will be removed by centrifugation and protein concentration will be determined. The activity of enzymes will be determined using a LCMS-based method.
The following mRNA and enzyme activity levels of the proteins controlling the local estrogen metabolism will be assessed;
- 17beta-hydroxysteroid dehydrogenase type 1 (HSD17B1)
- 17beta-hydroxysteroid dehydrogenase type 2 (HSD17B2)
- Steroid sulphatase (STS)
- Estrogen sulphotransferase (SULT1E1)
- Aromatase (ARO)
Blood analyses will be assessed in collaboration with prof. Auriola of the Eastern University Finland (34).
The most recently developed Multiplex steroid analyse protocol allows the identification and quantification of the following steroids; estradiol, cortisol, cortisone, estriol, aldosterone, 17OH-pregnenolone, 11deoxycortisol, estrone, DHEA, testosterone, 17OH-progesterone, androstrome, etiocholanolone, dht, androstenedione, pregnenolone, 21OH-progestreone, progesterone.
Additional steroids will be analysed at the laboratory at the Maastricht University Medical Center (MUMC) by LCMS.
- Estrone sulphate (E1S)
In case of specific new research questions or interest on the analyses of other parameters and metabolites, separate METC protocol or appropriate amendments will by applied.
|- Primary outcome||The primary outcome will be the difference between premenopausal, postmenopausal and endometrial cancer patients in the local tissue enzyme mRNA levels analysed by rt-PCR and described as fold change compared to housekeeping genes. Enzyme activity levels analysed by LCMS for HSD17B1, HSD17B2, STS, SULT1E1, ARO will be described in pmol/mg/hour. Systemic serum steroid levels (see for specification section 5.3 study procedures).will be measured and described in ng/ml or pg/ml.|
|- Secondary outcome||Secondary objectives are; differences in BMI, presence of diabetes, presence of hypertension, hormone use, parity, and history of other malignancies.|
|- Timepoints||Endpoint all inclusions01-11-2017, after all inclusions the analyses will be preformed.|
|- Trial web site|
|- CONTACT FOR PUBLIC QUERIES||Drs. Karlijn Cornel|
|- CONTACT for SCIENTIFIC QUERIES||Drs. Karlijn Cornel|
|- Sponsor/Initiator ||Maxima Medical Center, Veldhoven|
(Source(s) of Monetary or Material Support)
|Maxima Medical Center, KWF Kankerbestrijding|
|- Brief summary||Rationale: Endometrial cancer is the most common gynaecological malignancy in the western world with over 320.00 new patients a year worldwide (1). Although good 5 year survival ranging between 74% to 91%, 20-30% will develop recurrence or are diagnosed at high stage (1). For those patients besides chemotherapy and/or hormonal therapy (which is only successful in 30% of the cases) no other options are available. |
It is well known that exposure to estrogens increases the risk of the development of endometrial cancer. However, little is known about the complete estrogen metabolism, i.e. the way estrogens are supplied to endometrial cancer, which can occur via the circulation, or through the local generation of steroids.
Objective: To investigate the complete estrogen metabolism in pre- and postmenopausal healthy women compared with endometrial cancer patients.
Our secondary objective is the detection of possible serum and/or endometrium specific risk factors in the development of endometrial cancer, patients’ prognosis in relation to specific serum and/or endometrium markers, novel interesting biomarkers for future therapeutic target.
Study design: We aim to conduct a prospective pilot cohort study investigating the estrogen metabolism in blood serum and endometrial (cancer) tissue.
Study population: Pre- and postmenopausal healthy women and endometrial cancer patients who underwent hysterectomy in our hospital can be included. An endometrial tissue sample and blood sample will be taken to investigate or objective.
Main study parameters/endpoints:
The main parameters are: the levels of enzymes involved in the local estrogen synthesis (HSD17B1, HSD17B2, STS, SULT1E1, ARO) in endometrial tissue and the systemic serum steroid levels. Premenopausal, postmenopausal women and endometrial cancer patients will be compared.
|- Main changes (audit trail)|
|- RECORD||20-mrt-2016 - 25-mei-2016|
- Indien u gegevens wilt toevoegen of veranderen, kunt u een mail sturen naar email@example.com